Evidence map›Paper›PMID 20590567›Full record

ArticleBritish journal of pharmacology2010

Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Brian D Hudson, Terence E Hébert, Melanie E M Kelly

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Crosstalk between the MCellular signalling · 2020
    Review
  11. Cannabinoids as anticancer therapeutic agents.Cell cycle (Georgetown, Tex.) · 2020
    Review
  12. Article
  13. Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling.Frontiers in molecular neuroscience · 2019
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CBJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Brian D HudsonDepartment of Pharmacology, Dalhousie University, Halifax, NS, Canada.
Terence E Hébert
Melanie E M Kelly
Dalhousie University · CAMcGill University · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

background and purposeThe CB(1) cannabinoid receptor and the beta(2)-adrenoceptor are G protein-coupled receptors (GPCRs) co-expressed in many tissues. The present study examined physical and functional interactions between these receptors in a heterologous expression system and in primary human ocular cells. EXPERIMENTAL APPROACH: Physical interactions between CB(1) receptors and beta(2)-adrenoceptors were assessed using bioluminescence resonance energy transfer (BRET). Functional interactions between these receptors were evaluated by examining receptor trafficking, as well as extracellular signal-regulated kinase (ERK) and cyclic AMP response element binding protein (CREB) signalling. KEY

resultsPhysical interactions between CB(1) receptors and beta(2)-adrenoceptors were demonstrated using BRET. In human embryonic kidney (HEK) 293H cells, co-expression of beta(2)-adrenoceptors tempered the constitutive activity and increased cell surface expression of CB(1) receptors. Co-expression altered the signalling properties of CB(1 )receptors, resulting in increased Galpha(i)-dependent ERK phosphorylation, but decreased non-Galpha(i)-mediated CREB phosphorylation. The CB(1) receptor inverse agonist AM251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) attenuated beta(2)-adrenoceptor-pERK signalling in cells expressing both receptors, while the CB(1) receptor neutral antagonist O-2050 ((6aR,10aR)-3-(1-methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran) did not. The actions of AM251 and O-2050 were further examined in primary human trabecular meshwork (HTM) cells, which are ocular cells endogenously co-expressing CB(1) receptors and beta(2)-adrenoceptors. In HTM cells, as in HEK 293H cells, AM251 but not O-2050, altered the beta(2)-adrenoceptor-pERK response. CONCLUSION AND IMPLICATIONS: A complex interaction was demonstrated between CB(1) receptors and beta(2)-adrenoceptors in HEK 293H cells. As similar functional interactions were also observed in HTM cells, such interactions may affect the pharmacology of these receptors in tissues where they are endogenously co-expressed.

Indexed as

Adrenergic beta-2 Receptor AntagonistsCell LineCyclic AMP Response Element-Binding ProteinDronabinolEnergy TransferExtracellular Signal-Regulated MAP KinasesHumansPiperidinesPyransPyrazolesReceptor, Cannabinoid, CB1Receptor Cross-TalkReceptors, Adrenergic, beta-2Signal Transduction(6aR,10aR)-3-(1-methansulfonylamino-4-hexyn-6-yl)6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyranAdrenergic beta-2 Receptor AntagonistsAM 251Cyclic AMP Response Element-Binding ProteinDronabinolExtracellular Signal-Regulated MAP KinasesPiperidinesPyransPyrazolesReceptor, Cannabinoid, CB1Receptors, Adrenergic, beta-2

Identifiers

PMID20590567
PMCPMC2931563
OpenAlexW1667252614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.